Compare DexCom, Inc. (DXCM) vs MakeMyTrip Ltd (MMYT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs MakeMyTrip Ltd — how do they compare? DexCom, Inc. trades at $77.44 (market cap $28.06B), while MakeMyTrip Ltd trades at $54.23 (market cap $5.24B). The key difference: DexCom, Inc. is far larger — about 5.4× MakeMyTrip Ltd's market cap, and DexCom, Inc. is trading nearer its 52-week high, MakeMyTrip Ltd nearer its low. Which is the better fit depends on your goals.
| DXCM | MMYT | |
|---|---|---|
Market Cap | $28.06B | $5.24B |
Sector | Health | Technology |
52-Week High | $89.53 | $103.21 |
52-Week Low | $54.84 | $36.30 |
Enterprise Value | $27.03B | $5.89B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DexCom (DXCM) trades at $74.12, down 2.92% on the day, with a bullish technical signal from moving averages. The company demonstrates strong fundamentals with consistent revenue growth, expanding profit margins, and a track record of beating earnings estimates. Recent regulatory approvals for its G7 15-day CGM in Canada and pediatric clearance for its Stelo OTC system in the U.S. highlight ongoing product expansion.
The investment thesis centers on DexCom's leadership in the growing CGM market, supported by strong financial execution and analyst optimism. Key risks include competition from Abbott, the commercial unproven nature of expansion into non-insulin Type 2 diabetes patients, and potential disruption from GLP-1 drug adoption. The consensus price target of $84.33 suggests ~14% upside from current levels.
MMYT trades at $54.29, down 2.62% today amid a bearish technical signal, though it remains above key support at $52. The company shows strong revenue growth with $978M in 2025 and consistent earnings beats, but faces a high P/E of 153.56. Recent news highlights volatility from travel disruptions, yet analyst consensus remains strongly bullish with 73% buy ratings.
Outlook is mixed: robust fundamentals and analyst support suggest long-term potential, but high valuation and projected profit margin compression to 4.96% in 2026 pose risks. Investors should weigh growth against debt increases and market sensitivity to travel sector headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About MakeMyTrip Ltd
MakeMyTrip Ltd. is a leading online travel company in India, providing a comprehensive range of travel services and products, including air tickets, hotels, holiday packages, rail tickets, and bus tickets. The company operates its primary websites and mobile apps under the brands MakeMyTrip, Goibibo, and RedBus. MMYT serves as a key intermediary in India's fragmented travel market, leveraging its platform to offer convenience and competitive pricing to consumers and businesses.
Read more on MMYT →
